SPAC Averin Capital Acquisition files for a $250 million IPO, targeting health and life sciences sectors
February 18, 2026 News
SPAC Averin Capital Acquisition prices $250 million IPO, led by former Flagship partner David Berry
Averin Capital Acquisition, a blank check company backed by Averin Capital targeting health and technology businesses, raised $250 million by offering 25 million units at $10. Each unit consists of one share of common stock and one-sixth of a warrant, exercisable at $11.50.
IPO Overview
Averin Capital Acquisition, a blank check company targeting health and life sciences, filed on Friday with the SEC to raise up to $250 million in an initial public offering.
The New York, NY-based company plans to raise $250 million by offering 25 million units at a price of $10. Each unit consists of one share of common stock and one-sixth of one warrant, exercisable at $11.50.
Averin Capital Acquisition is set to be led by Chairman and CEO David Berry, who co-founded Averin Capital in 2023, and has served as its Managing Partner since. He currently serves as Chairman of Osler Diagnostics, and as a Director at Oaktree Acquisition III Life Sciences, Hologen, Biolinq, and Salma Health. He is joined by CFO Alex Lau, who has served as the Partner and Head of Operations at Averin Capital since February 2025.
The New York, NY-based company was founded in 2025 and plans to list on the Nasdaq under the symbol ACAAU. Averin Capital Acquisition filed confidentially on November 17, 2025. Deutsche Bank is the sole bookrunner on the deal.
About the Company
Averin Capital Acquisition Corp. is a blank check company formed to pursue a merger, share exchange, asset acquisition, or similar business combination with one or more operating businesses. The company has not yet selected a target and is focused on identifying businesses with strong growth potential and attractive long-term fundamentals. Its strategy is informed by the CEO’s background in the healthcare sector, which positions the team to evaluate opportunities in health, life sciences, and related industries, while remaining flexible to pursue compelling transactions across other sectors. We intend to seek to acquire companies that we believe: are operating at the intersection of technology and health that we believe have the potential to create lasting value and shape the future of human health; are led by visionary entrepreneurs at the forefront of innovation; are ready to operate in the scrutiny of public markets, with strong management, corporate governance and reporting policies in place; can benefit from our operational expertise, experience and strategic insights; offer a what we believe to be a unique value proposition with a durable foundation and transformational potential that can be substantiated during our detailed due diligence process; and are at an inflection point, such as those requiring additional management expertise, are able to innovate by developing new products or services.